RU2014135406A - Модифицированные эпитопы для усиления ответов cd4+ т-клеток - Google Patents
Модифицированные эпитопы для усиления ответов cd4+ т-клеток Download PDFInfo
- Publication number
- RU2014135406A RU2014135406A RU2014135406A RU2014135406A RU2014135406A RU 2014135406 A RU2014135406 A RU 2014135406A RU 2014135406 A RU2014135406 A RU 2014135406A RU 2014135406 A RU2014135406 A RU 2014135406A RU 2014135406 A RU2014135406 A RU 2014135406A
- Authority
- RU
- Russia
- Prior art keywords
- amino acids
- sequence
- peptide
- cell epitope
- epitope
- Prior art date
Links
- 238000005728 strengthening Methods 0.000 title 1
- 235000001014 amino acid Nutrition 0.000 claims abstract 29
- 150000001413 amino acids Chemical class 0.000 claims abstract 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 22
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract 21
- 238000000034 method Methods 0.000 claims abstract 19
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims abstract 8
- 230000002163 immunogen Effects 0.000 claims abstract 7
- 102000043131 MHC class II family Human genes 0.000 claims abstract 4
- 108091054438 MHC class II family Proteins 0.000 claims abstract 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract 4
- 239000000427 antigen Substances 0.000 claims abstract 4
- 230000000890 antigenic effect Effects 0.000 claims abstract 4
- 102000036639 antigens Human genes 0.000 claims abstract 4
- 108091007433 antigens Proteins 0.000 claims abstract 4
- 230000001461 cytolytic effect Effects 0.000 claims abstract 4
- 230000000694 effects Effects 0.000 claims abstract 4
- 235000018102 proteins Nutrition 0.000 claims abstract 4
- 108090000623 proteins and genes Proteins 0.000 claims abstract 4
- 102000004169 proteins and genes Human genes 0.000 claims abstract 4
- 235000018417 cysteine Nutrition 0.000 claims abstract 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract 3
- 230000003213 activating effect Effects 0.000 claims abstract 2
- 239000013566 allergen Substances 0.000 claims abstract 2
- 238000000338 in vitro Methods 0.000 claims abstract 2
- 239000012678 infectious agent Substances 0.000 claims abstract 2
- 210000004976 peripheral blood cell Anatomy 0.000 claims abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464462—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4648—Bacterial antigens
- A61K39/464817—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464839—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/56—Kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/05—Adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Insects & Arthropods (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
Abstract
1. Способ получения популяции активированных не цитолитических CD4+ Т-клеток in vitro, где способ включает стадию введения в популяцию клеток периферической крови выделенного иммуногенного пептида длиной от 9 до 50 аминокислот, где пептид содержит:a) Т-клеточный эпитоп из 8 или 9 аминокислот антигенного белка для МНС класса II иb) последовательность от 1 до 6 аминокислот с n-концевой и/или c-концевой стороны от последовательности эпитопа из 8 или 9 аминокислот из а), содержащую восстанавливающий остаток цистеина, где указанная последовательность от 1 до 6 аминокислот не содержит последовательности мотива с окислительно-восстановительной активностью С-xx-[CST] или [CST]-xx-C.2. Способ по п. 1, где пептид представляет собой искусственный пептид.3. Способ по п. 1, где последовательность, определенная в части b), содержит только один цистеин.4. Способ по п. 1, где иммуногенный пептид имеет длину от 9 до 20 аминокислот.5. Способ по п. 1, где указанный остаток цистеина локализован непосредственно с N- или С-конца от эпитопа из 8 или 9 аминокислот, без аминокислот между последовательностью указанного эпитопа и указанным остатком цистеина.6. Способ по п. 1, где указанный Т-клеточный эпитоп представляет собой Т-клеточный эпитоп инфекционного агента.7. Способ по п. 1, где указанный Т-клеточный эпитоп представляет собой Т-клеточный эпитоп собственного антигена, аллергена, аллофактора или антигена аллотрансплантата.8. Способ по п. 1, где указанный Т-клеточный эпитоп представляет собой Т-клеточный эпитоп, специфический или предпочтительный для опухоли.9. Выделенный иммуногенный пептид длиной от 9 до 30 аминокислот, способный активировать нецитолитические CD4+ Т-клетки и содержащий:a) Т-клеточный эпитоп из 8 или 9 аминокислот антигенно
Claims (15)
1. Способ получения популяции активированных не цитолитических CD4+ Т-клеток in vitro, где способ включает стадию введения в популяцию клеток периферической крови выделенного иммуногенного пептида длиной от 9 до 50 аминокислот, где пептид содержит:
a) Т-клеточный эпитоп из 8 или 9 аминокислот антигенного белка для МНС класса II и
b) последовательность от 1 до 6 аминокислот с n-концевой и/или c-концевой стороны от последовательности эпитопа из 8 или 9 аминокислот из а), содержащую восстанавливающий остаток цистеина, где указанная последовательность от 1 до 6 аминокислот не содержит последовательности мотива с окислительно-восстановительной активностью С-xx-[CST] или [CST]-xx-C.
2. Способ по п. 1, где пептид представляет собой искусственный пептид.
3. Способ по п. 1, где последовательность, определенная в части b), содержит только один цистеин.
4. Способ по п. 1, где иммуногенный пептид имеет длину от 9 до 20 аминокислот.
5. Способ по п. 1, где указанный остаток цистеина локализован непосредственно с N- или С-конца от эпитопа из 8 или 9 аминокислот, без аминокислот между последовательностью указанного эпитопа и указанным остатком цистеина.
6. Способ по п. 1, где указанный Т-клеточный эпитоп представляет собой Т-клеточный эпитоп инфекционного агента.
7. Способ по п. 1, где указанный Т-клеточный эпитоп представляет собой Т-клеточный эпитоп собственного антигена, аллергена, аллофактора или антигена аллотрансплантата.
8. Способ по п. 1, где указанный Т-клеточный эпитоп представляет собой Т-клеточный эпитоп, специфический или предпочтительный для опухоли.
9. Выделенный иммуногенный пептид длиной от 9 до 30 аминокислот, способный активировать нецитолитические CD4+ Т-клетки и содержащий:
a) Т-клеточный эпитоп из 8 или 9 аминокислот антигенного белка для MHC класса II и
b) последовательность от 1 до 6 аминокислот с n-концевой и/или c-концевой стороны от последовательности эпитопа из 8 или 9 аминокислот из а), содержащую восстанавливающий остаток цистеина, где указанная последовательность от 1 до 6 аминокислот не содержит последовательности мотива с окислительно-восстановительной активностью С-хх-[CST] или [CST]-xx-С, для применения в качестве лекарственного средства.
10. Пептид по п. 9, где пептид представляет собой искусственный пептид.
11. Пептид по п. 9, где последовательность, определенная в части b), содержит только один цистеин.
12. Пептид по п. 9, имеющий длину от 9 до 20 аминокислот.
13. Применение пептида по любому из пп. 9-12 в лечении или предотвращении инфекционного заболевания, аутоиммунного заболевания, аллергического заболевания или опухоли.
14. Способ лечения или предотвращения нарушения, включающий стадию введения эффективного количества выделенного иммуногенного пептида от 9 до 30 аминокислот, где указанный пептид содержит:
a) Т-клеточный эпитоп из 8 или 9 аминокислот антигенного белка для МНС класса II и
b) последовательность от 1 до 6 аминокислот с n-концевой и/или c-концевой стороны от последовательности эпитопа из 8 или 9 аминокислот из а), содержащую восстанавливающий остаток цистеина, где указанная последовательность от 1 до 6 аминокислот не содержит последовательности мотива с окислительно-восстановительной активностью С-xx-[CST] или [CST]-xx-С,
где нарушение выбрано из группы, состоящей из инфекционного заболевания, аутоиммунного заболевания, аллергического заболевания, опухоли и иммунного ответа, нейтрализующего аллофактор.
15. Способ по п. 14, где пептид представляет собой искусственный пептид.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261592404P | 2012-01-30 | 2012-01-30 | |
GB1201511.1 | 2012-01-30 | ||
US61/592,404 | 2012-01-30 | ||
GBGB1201511.1A GB201201511D0 (en) | 2012-01-30 | 2012-01-30 | Modified epitopes for boosting CD4+ T-cell responses |
PCT/BE2013/000006 WO2013113076A1 (en) | 2012-01-30 | 2013-01-30 | Modified epitopes for boosting cd4+ t-cell responses |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2014135406A true RU2014135406A (ru) | 2016-03-27 |
RU2724994C2 RU2724994C2 (ru) | 2020-06-29 |
Family
ID=45876280
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014135406A RU2724994C2 (ru) | 2012-01-30 | 2013-01-30 | Модифицированные эпитопы для усиления ответов cd4+ т-клеток |
Country Status (13)
Country | Link |
---|---|
US (2) | US10899795B2 (ru) |
EP (2) | EP3756675A1 (ru) |
JP (2) | JP6285368B2 (ru) |
KR (2) | KR102228843B1 (ru) |
CN (1) | CN104220080B (ru) |
AU (1) | AU2013214700B2 (ru) |
BR (1) | BR112014017862A2 (ru) |
CA (1) | CA2863126A1 (ru) |
GB (1) | GB201201511D0 (ru) |
HK (1) | HK1204283A1 (ru) |
RU (1) | RU2724994C2 (ru) |
WO (1) | WO2013113076A1 (ru) |
ZA (1) | ZA201405197B (ru) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2476437B1 (en) | 2006-08-11 | 2018-11-28 | Life Sciences Research Partners VZW | Immunogenic peptides and their use in immune disorders |
AU2009214039B2 (en) | 2008-02-14 | 2013-09-19 | Katholieke Universiteit Leuven | Immunogenic control of tumours and tumour cells |
EP2244733B1 (en) | 2008-02-14 | 2015-06-17 | Life Sciences Research Partners VZW | Immunotherapy targeting intracellular pathogens |
ES2924027T3 (es) | 2010-11-25 | 2022-10-04 | Imcyse Sa | Péptidos inmunogénicos para su uso en la prevención y/o tratamiento de enfermedades infecciosas, enfermedades autoinmunitarias, respuestas inmunitarias a alofactores, enfermedades alérgicas, tumores, rechazo de injerto y respuestas inmunitarias contra vectores virales usados para terapia génica o vacunación génica |
GB201201511D0 (en) | 2012-01-30 | 2012-03-14 | Univ Leuven Kath | Modified epitopes for boosting CD4+ T-cell responses |
GB201309469D0 (en) | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
WO2015132248A2 (en) * | 2014-03-03 | 2015-09-11 | Vrije Universiteit Brussel (Vub) | Sequamers - a novel non-natural type of peptide libraries randomly constrained by their primary sequences |
GB201418433D0 (en) * | 2014-10-17 | 2014-12-03 | Imcyse Sa | Novel immunogenic peptides |
EP3556778A1 (en) * | 2015-03-30 | 2019-10-23 | Osaka University | Immunizing peptide, method for producing immunizing peptide, pharmaceutical composition for immune disorders containing same, and method for treating immune disorders |
US10729791B2 (en) | 2015-05-18 | 2020-08-04 | Imcyse Sa | Animal models for evaluating pharmaceutical compounds |
GB201511546D0 (en) * | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
WO2017050966A1 (en) | 2015-09-25 | 2017-03-30 | Imcyse Sa | Improved methods and compounds for eliminating immune responses to therapeutic agents |
RU2018136760A (ru) | 2016-04-19 | 2020-05-19 | Имсис Са | НОВЫЕ ИММУНОГЕННЫЕ CD1d-СВЯЗЫВАЮЩИЕ ПЕПТИДЫ |
CU24596B1 (es) * | 2017-03-09 | 2022-05-11 | Imcyse Sa | Péptidos obtenidos a partir de insulina útiles en el tratamiento de diabetes |
US10850981B2 (en) | 2017-04-25 | 2020-12-01 | Ica Trinova, Llc | Methods of producing a gas at a variable rate |
US11912568B2 (en) | 2018-03-14 | 2024-02-27 | Ica Trinova, Llc | Methods of producing a gas at a controlled rate |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4599231A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
AU579148B2 (en) | 1984-03-09 | 1988-11-17 | Scripps Clinic And Research Foundation | Synthetic hepatitis b virus vaccine including both t cell and b cell determinants |
US4886782A (en) | 1987-02-26 | 1989-12-12 | The United States Of America As Represented By The Department Of Health And Human Services | Malarial immunogen |
US5433948A (en) | 1990-02-13 | 1995-07-18 | Thomas; Wayne R. | Cloning and sequencing of allergens of dermatophagoides (house dust mite) |
AU650911B2 (en) | 1990-09-27 | 1994-07-07 | Syntello Vaccine Development Kb | Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus |
US5912170A (en) | 1991-03-07 | 1999-06-15 | The General Hospital Corporation | Redirection of cellular immunity by protein-tyrosine kinase chimeras |
JPH07502890A (ja) | 1991-10-16 | 1995-03-30 | イミユロジク・フアーマシユーチカル・コーポレーシヨン | ダーマトファゴイデス(Dermatophagoides)(家ほこりダニ)からの主要なアレルゲンのT細胞エピトープ |
US7252829B1 (en) * | 1998-06-17 | 2007-08-07 | Idm Pharma, Inc. | HLA binding peptides and their uses |
US5589582A (en) | 1992-10-27 | 1996-12-31 | Biotransplant, Inc. | Polynucleotides en coding porcine cytokines |
US5633234A (en) | 1993-01-22 | 1997-05-27 | The Johns Hopkins University | Lysosomal targeting of immunogens |
JP3926839B2 (ja) * | 1993-09-14 | 2007-06-06 | エピミューン,インコーポレイティド | 万能dr−結合性ペプチドを用いる免疫応答の改変 |
US5824315A (en) | 1993-10-25 | 1998-10-20 | Anergen, Inc. | Binding affinity of antigenic peptides for MHC molecules |
US8791237B2 (en) | 1994-11-08 | 2014-07-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of non-hodgkins lymphoma |
DE69634855T2 (de) * | 1995-02-24 | 2006-05-18 | The General Hospital Corp., Boston | Neuorientierung der zellulären immunität durch rezeptorchimären |
US7157089B1 (en) | 1996-11-26 | 2007-01-02 | Stressgen Biotechnologies Corporation | Immune responses using compositions containing stress proteins |
WO1999021979A1 (en) | 1997-10-28 | 1999-05-06 | Maxygen, Inc. | Human papillomavirus vectors |
NO315238B1 (no) | 1998-05-08 | 2003-08-04 | Gemvax As | Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy |
US20030152581A1 (en) | 1998-07-30 | 2003-08-14 | Jean-Marie Saint-Remy | Compound and method for the prevention and/or the treatment of allergy |
AR020102A1 (es) | 1998-07-30 | 2002-04-10 | Ucb Sa | Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento |
CA2350911A1 (en) | 1998-11-16 | 2000-05-25 | Board Of Regents, The University Of Texas System | Hiv-specific t-cell induction |
US7780882B2 (en) * | 1999-02-22 | 2010-08-24 | Georgetown University | Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent |
EP1252309A2 (en) | 2000-01-28 | 2002-10-30 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services | Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1 |
GB0006437D0 (en) | 2000-03-17 | 2000-05-10 | Leuven Res & Dev Vzw | Compounds for the modulation of allergen sensitivity by antigens sharing T cell epitopes with allergens |
US20030104570A1 (en) | 2000-06-26 | 2003-06-05 | Cabezon Silva Teresa Elisa Virginia | Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest |
US7049413B2 (en) | 2001-05-18 | 2006-05-23 | Ludwig Institute For Cancer Research | MAGE-A3 peptides presented by HLA class II molecules |
WO2002097070A1 (en) | 2001-05-30 | 2002-12-05 | Fondazione Telethon | Ex-vivo isolated cd25+cd4+ t cells with immunosuppressive activity and uses thereof |
ATE424418T1 (de) | 2001-10-03 | 2009-03-15 | Unilever Nv | Kohlenhydratbindungsdomäne enthaltende fusionsproteine zur verabreichung von therapeutischen und anderen stoffen und zusammensetzungen in denen die fusionsproteine enthalten sind |
WO2003072731A2 (en) * | 2002-02-21 | 2003-09-04 | Apovia, Inc. | STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS |
US20100183652A1 (en) | 2002-02-21 | 2010-07-22 | Mark Page | STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS |
AU2003254950A1 (en) | 2002-08-26 | 2004-03-11 | Kirin Beer Kabushiki Kaisha | Peptides and drugs containing the same |
EP2267023B1 (en) | 2002-09-12 | 2015-02-11 | Oncotherapy Science, Inc. | KDR peptides and vaccines comprising the same |
JP2004147649A (ja) | 2002-10-11 | 2004-05-27 | Kumamoto Technology & Industry Foundation | 頭頚部癌の抗原 |
WO2005012502A2 (en) | 2003-03-28 | 2005-02-10 | Idm Pharma, Inc. | Methods of identifying optimal variants of peptide epitopes |
US7651855B2 (en) | 2003-04-17 | 2010-01-26 | The Trustees Of The University Of Pennsylvania | Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses |
US20070014807A1 (en) | 2003-09-03 | 2007-01-18 | Maida Anthony E Iii | Multiplex vaccine |
GB0324265D0 (en) | 2003-10-16 | 2003-11-19 | Medical Res Council | Peptide |
WO2005042575A2 (en) | 2003-10-30 | 2005-05-12 | Pharmexa A/S | Method for down-regulation of vegf |
AU2005265182B2 (en) * | 2004-06-17 | 2012-06-21 | Mannkind Corporation | Epitope analogs |
JP2008044848A (ja) | 2004-11-30 | 2008-02-28 | Univ Kurume | Hla−a24拘束性腫瘍抗原ペプチド |
US8252893B2 (en) | 2005-01-31 | 2012-08-28 | Board Of Trustees Of The University Of Arkansas | CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof |
WO2007027954A2 (en) | 2005-08-30 | 2007-03-08 | Children's Hospital & Research Center At Oakland | Methods for identifying an epitope of a polypeptide, chlamydial antigenic polypeptides identified thereby, and methods of use thereof |
US10183986B2 (en) | 2005-12-15 | 2019-01-22 | Industrial Technology Research Institute | Trimeric collagen scaffold antibodies |
GB0603081D0 (en) | 2006-02-15 | 2006-03-29 | Dynal Biotech Asa Oslo | Method |
FR2898275B1 (fr) | 2006-03-10 | 2012-12-14 | Genethon | Cellules t regulatrices cd4+cd25+specifiques pour la greffe de cellules hematopoietiques et la tolerance immunitaire |
WO2007135684A2 (en) | 2006-05-22 | 2007-11-29 | Hadasit Medical Research Services & Development Limited | Method of treatment of anti-cd4 autoimmunity |
EP2476437B1 (en) * | 2006-08-11 | 2018-11-28 | Life Sciences Research Partners VZW | Immunogenic peptides and their use in immune disorders |
US20100203083A1 (en) | 2007-05-31 | 2010-08-12 | Medigene Ag | Mutated structural protein of a parvovirus |
EP2205252B1 (en) | 2007-09-27 | 2017-04-05 | The Board Of Trustees Of The University Of Arkansas | Inhibition of dendritic cell-driven regulatory t cell activation and potentiation of tumor antigen-specific t cell responses by interleukin-15 and map kinase inhibitor |
US8091871B2 (en) | 2008-02-05 | 2012-01-10 | Cooper-Standard Automotive Inc. | Axially damped hydraulic mount assembly |
US7848608B2 (en) | 2008-02-05 | 2010-12-07 | Adc Telecommunications, Inc. | Fiber routing system with drop-in device |
US20090199143A1 (en) | 2008-02-06 | 2009-08-06 | Mentor Graphics, Corp. | Clock tree synthesis graphical user interface |
US8262373B2 (en) | 2008-02-07 | 2012-09-11 | Emerson Climate Technologies, Inc. | Compressor having wire retainer |
CN101978024B (zh) | 2008-02-08 | 2014-05-07 | 晶美晟光电材料(南京)有限公司 | 包含环戊烷基团的液晶 |
EP2623125A1 (en) | 2008-02-14 | 2013-08-07 | Life Sciences Research Partners VZW | Elimination of immune responses to viral vectors |
EP2249855B1 (en) | 2008-02-14 | 2017-03-22 | Life Sciences Research Partners VZW | Immunogenic peptides and their use in transplantation |
AU2009214039B2 (en) | 2008-02-14 | 2013-09-19 | Katholieke Universiteit Leuven | Immunogenic control of tumours and tumour cells |
EP2249864B1 (en) * | 2008-02-14 | 2016-05-04 | Life Sciences Research Partners VZW | Strategies to prevent and/or treat immune responses to soluble allofactors |
WO2009101207A1 (en) | 2008-02-14 | 2009-08-20 | Life Sciences Research Partners Vzw | Cd4+ t-cells with cytolytic properties |
EP2244733B1 (en) | 2008-02-14 | 2015-06-17 | Life Sciences Research Partners VZW | Immunotherapy targeting intracellular pathogens |
WO2009106073A2 (en) | 2008-02-28 | 2009-09-03 | Dako Denmark A/S | Mhc multimers in borrelia diagnostics and disease |
WO2010037395A2 (en) | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
EP2413964B1 (en) * | 2009-04-01 | 2019-11-13 | University of Miami | Vaccine compositions and methods of use thereof |
JP5942296B2 (ja) | 2010-03-29 | 2016-06-29 | サントル・ナショナル・ドゥ・ラ・ルシェルシュ・シャンティフィクCentre National De La Recherche Scientifique | 少なくとも1つのcxxcモチーフを含むポリペプチドと異種抗原とを含む医薬組成物、及びその使用 |
ES2924027T3 (es) | 2010-11-25 | 2022-10-04 | Imcyse Sa | Péptidos inmunogénicos para su uso en la prevención y/o tratamiento de enfermedades infecciosas, enfermedades autoinmunitarias, respuestas inmunitarias a alofactores, enfermedades alérgicas, tumores, rechazo de injerto y respuestas inmunitarias contra vectores virales usados para terapia génica o vacunación génica |
GB201201511D0 (en) | 2012-01-30 | 2012-03-14 | Univ Leuven Kath | Modified epitopes for boosting CD4+ T-cell responses |
GB201309469D0 (en) | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
GB201319160D0 (en) | 2013-10-30 | 2013-12-11 | Imcyse Sa | Methods for induction of antigen-specific regulatory t cells |
GB201418433D0 (en) | 2014-10-17 | 2014-12-03 | Imcyse Sa | Novel immunogenic peptides |
WO2017050966A1 (en) | 2015-09-25 | 2017-03-30 | Imcyse Sa | Improved methods and compounds for eliminating immune responses to therapeutic agents |
-
2012
- 2012-01-30 GB GBGB1201511.1A patent/GB201201511D0/en not_active Ceased
-
2013
- 2013-01-30 KR KR1020207000369A patent/KR102228843B1/ko active IP Right Grant
- 2013-01-30 CN CN201380007164.0A patent/CN104220080B/zh active Active
- 2013-01-30 WO PCT/BE2013/000006 patent/WO2013113076A1/en active Application Filing
- 2013-01-30 AU AU2013214700A patent/AU2013214700B2/en active Active
- 2013-01-30 US US14/375,324 patent/US10899795B2/en active Active
- 2013-01-30 RU RU2014135406A patent/RU2724994C2/ru not_active Application Discontinuation
- 2013-01-30 JP JP2014553584A patent/JP6285368B2/ja active Active
- 2013-01-30 EP EP19178529.4A patent/EP3756675A1/en active Pending
- 2013-01-30 CA CA2863126A patent/CA2863126A1/en not_active Abandoned
- 2013-01-30 BR BR112014017862A patent/BR112014017862A2/pt not_active IP Right Cessation
- 2013-01-30 EP EP13709300.1A patent/EP2809332A1/en not_active Ceased
- 2013-01-30 KR KR20147021391A patent/KR20140128977A/ko not_active Application Discontinuation
-
2014
- 2014-07-16 ZA ZA2014/05197A patent/ZA201405197B/en unknown
-
2015
- 2015-05-21 HK HK15104876.4A patent/HK1204283A1/xx unknown
-
2017
- 2017-11-29 JP JP2017229125A patent/JP6931598B2/ja active Active
-
2020
- 2020-12-22 US US17/130,192 patent/US20210188913A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2724994C2 (ru) | 2020-06-29 |
AU2013214700B2 (en) | 2017-09-28 |
KR20140128977A (ko) | 2014-11-06 |
EP3756675A1 (en) | 2020-12-30 |
JP6285368B2 (ja) | 2018-02-28 |
GB201201511D0 (en) | 2012-03-14 |
JP2018076329A (ja) | 2018-05-17 |
EP2809332A1 (en) | 2014-12-10 |
HK1204283A1 (en) | 2015-11-13 |
US20210188913A1 (en) | 2021-06-24 |
KR102228843B1 (ko) | 2021-03-18 |
CN104220080A (zh) | 2014-12-17 |
ZA201405197B (en) | 2015-10-28 |
AU2013214700A1 (en) | 2014-07-24 |
JP6931598B2 (ja) | 2021-09-08 |
KR20200010557A (ko) | 2020-01-30 |
CA2863126A1 (en) | 2013-08-08 |
CN104220080B (zh) | 2018-10-12 |
BR112014017862A2 (pt) | 2017-06-27 |
JP2015506365A (ja) | 2015-03-02 |
WO2013113076A1 (en) | 2013-08-08 |
US20140370044A1 (en) | 2014-12-18 |
US10899795B2 (en) | 2021-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2014135406A (ru) | Модифицированные эпитопы для усиления ответов cd4+ т-клеток | |
RU2013128866A (ru) | Иммуногенные пептиды для применения в профилактике и/или лечении инфекционных заболеваний, аутоиммунных заболеваний, иммунных ответов на аллогенные факторы, аллергических заболеваний, опухолей, отторжения трансплантата и иммунных ответов против вирусных векторов, используемых для генной терапии или генной вакцинации | |
AU2019250206A1 (en) | Novel immunogenic peptides | |
RU2010110567A (ru) | Пептид foxm1 и включающее его медицинское средство | |
RU2010110545A (ru) | Cdh3-пептид и включающее его лекарственное средство | |
AU2017279583B2 (en) | Liquid Formulation Of Protein Conjugate Comprising The Oxyntomodulin And An Immunoglobulin Fragment | |
JP2018504419A5 (ru) | ||
RU2019126232A (ru) | Пептиды и способы для лечения диабета | |
RU2008136324A (ru) | Желудочно-кишечный пролиферативный фактор и его применения | |
JP2019514895A5 (ru) | ||
MX2021002543A (es) | Proceso para la preparacion de composiciones de vacunas. | |
AR079114A1 (es) | Proteinas de enlace de antigenos anti-orai1 y usos de las mismas | |
RU2014127714A (ru) | ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile | |
EA201790680A1 (ru) | Вакцины против вируса иммунодефицита человека (вич), содержащие один или более эписенсусных (episensus) для популяции антигенов | |
TW201831681A (zh) | 使用人類間葉幹細胞以實現細胞性及體液性免疫的方法 | |
MX2022015734A (es) | Proteinas de exotoxina a modificadas. | |
NZ594198A (en) | Neil3 peptides and vaccines including the same | |
Yu et al. | Delivery of allergen powder for safe and effective epicutaneous immunotherapy | |
EA201690004A1 (ru) | Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение | |
EP1556513A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES MEDIATED BY THE HUMANE PAPILLOMA VIRUS | |
Wen et al. | A dendritic cells-targeting nano-vaccine by coupling polylactic-co-glycolic acid-encapsulated allergen with mannan induces regulatory T cells | |
RU2015144308A (ru) | Иммунная модуляция | |
NZ601980A (en) | Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same | |
AR041086A1 (es) | Vacuna | |
CN102526119A (zh) | 红色诺卡氏菌细胞壁骨架增强树突状细胞功能的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190305 |
|
FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20200213 |